Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its focus on heparin, biopharmaceuticals, and the impact of currency depreciation on its revenue [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [2]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [2][7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Renminbi [3]. - The main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Market Activity - On September 11, the stock price of Hepalink increased by 0.31%, with a trading volume of 75.5743 million yuan and a turnover rate of 0.48%, resulting in a total market capitalization of 18.825 billion yuan [1]. - The stock has seen a net outflow of 5.2287 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 11.54 yuan, with the current price near a support level of 12.80 yuan [6].

Group 1 - The Ministry of Industry and Information Technology has officially released the "2025 5G Factory Directory," which includes 560 projects across 48 industries, with Guangdong province contributing 49 projects [1] - Shenzhen has 10 factories listed in the 5G Factory Directory, including notable companies such as Haiprui, Mindray, and BYD, showcasing a diverse range of applications from pharmaceuticals to logistics and transportation [1] - The development of 5G factories is a key task for the large-scale growth of "5G + Industrial Internet," aimed at enhancing efficiency and driving technological innovation in manufacturing [2] Group 2 - Shenzhen has been at the forefront of 5G development, achieving full coverage of 5G infrastructure by 2020 and being selected as one of the first pilot cities for "5G + Industrial Internet" applications in 2024 [3] - The establishment of 5G factories is expected to enhance operational efficiency and reduce costs in the short term, while building competitive advantages and industry influence in the medium term, and providing a gateway to global digital economy participation in the long term [3] - The concentration of 5G factories in Shenzhen reflects its dual commitment to becoming an industrial city and a leader in the digital economy, serving as a core engine for high-quality economic development [3]

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares), primarily engaged in the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Position - As of June 30, 2025, the company had a market capitalization of 18.767 billion yuan, with a trading volume of 38.1828 million yuan and a turnover rate of 0.24% [1]. - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Investment Dynamics - The stock has seen a net outflow of 1.0654 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. - The average trading cost of the stock is 11.53 yuan, with the current price approaching a resistance level of 12.80 yuan, indicating potential for upward movement if the resistance is broken [6].

4、根据2024年年报，公司海外营收占比为93.04%，受益于人民币贬值。 来源：新浪证券-红岸工作室 9月8日，海普瑞涨0.46%，成交额6026.50万元，换手率0.37%，总市值192.66亿元。 异动分析 创新药+CRO概念+生物疫苗+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 2、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 3、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 (免责声明：分析内容来源于互联网，不构成投资建议，请投资者根据不同行情独立判断) 资金分析 今日主力净流入-310.40万，占比0.05%，行业排名91/158，该股当前无连续增减仓现象，主力趋势不明 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 呈交日期: 2025年9月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | - ...

Summary of Key Points Core Viewpoint - The financial performance of Haiprui Pharmaceutical Group shows a decline in revenue and net profit for the first half of 2025, indicating potential challenges in the company's operations and market conditions [2]. Group 1: Financial Performance - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71% [2]. - The net profit attributable to shareholders for the same period was 422 million yuan, reflecting a significant year-on-year decline of 36.44% [2]. Group 2: Shareholder and Market Activity - As of August 29, 2023, Haiprui's stock price increased by 0.16%, with a trading volume of 74.417 million yuan [1]. - The company experienced a net financing outflow of 2.4477 million yuan on August 29, with a total financing and securities balance of 268 million yuan [1]. - The number of shareholders decreased by 7.29% to 26,300 as of June 30, 2025 [2]. Group 3: Dividend and Institutional Holdings - Haiprui has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the eighth largest shareholder, increasing its holdings by 6.3765 million shares to 11.3176 million shares [3].

Core Viewpoint - In the first half of 2025, Haiprime (002399.SZ) reported mixed financial results, with a slight decline in revenue and a significant drop in net profit, while the adjusted net profit showed growth, indicating challenges and opportunities in its core business segments [2][4]. Financial Performance - Haiprime achieved operating revenue of 2.817 billion yuan, a year-on-year decrease of 0.71% [2]. - The net profit attributable to shareholders was 422 million yuan, down 36.44% year-on-year, primarily due to a significant one-time investment gain in the same period last year [4]. - The adjusted net profit, excluding non-recurring items, was 426 million yuan, an increase of 29.34% compared to 329 million yuan in the previous year [4]. - The net cash flow from operating activities was 1.049 billion yuan, a decline of 19.00% year-on-year, attributed to reduced cash receipts from sales and increased cash payments for goods and services [4]. Business Segment Analysis - The heparin business segment generated sales revenue of 2.229 billion yuan, a year-on-year increase of 1.26%, with a significant growth of over 30% in formulation sales, which amounted to 1.777 billion yuan, up 22.24% [5]. - The gross margin for the heparin formulation was 31.05%, while the raw material drug (API) segment faced challenges, with sales revenue of 452 million yuan, down 39.51%, and a gross margin of 23.82% due to low export prices and increased competition [5]. - The CDMO business segment reported sales revenue of 524 million yuan, a slight decrease of 6.56%, but with an improved gross margin of 36.58%, reflecting effective cost control and business optimization efforts [6]. Strategic Developments - Haiprime is facing intensified competition in the heparin market, necessitating the exploration of new business opportunities to sustain growth [7]. - The company has signed a distribution agreement with Zhejiang Yongtai Pharmaceutical Co., Ltd. to commercialize Gabapentin capsules in the U.S. market and is also advancing the commercialization of Foshapitan in collaboration with another pharmaceutical group [7]. - The innovative drug candidate H1710 has received approval for clinical trials and has shown significant anti-tumor effects in animal models, indicating the company's commitment to expanding its innovative drug portfolio [8]. - Haiprime aims to leverage its international operations and support Chinese pharmaceutical companies in entering European and American markets, although it faces challenges in market research, technology development, funding, and talent acquisition [8].

格隆汇8月29日丨海普瑞(09989.HK)发布公告，截至2025年6月30日止六个月，实现收入人民币27.91亿 元，同比减少1.3%；毛利为人民币8.09亿元，同比减少19.0%；母公司持有者的应占溢利为人民币4.22 亿元，同比减少36.4%；基本每股盈利人民币0.29元。报告期内，净利润同比有所下降，主要由于2024 年同期受大额一次性投资收益正向影响，对本报期利润同比变化影响较大。 ...

（原标题：海普瑞(002399.SZ)发布上半年业绩，归母净利润4.22亿元，同比下降36.44%） 智通财经APP讯，海普瑞(002399.SZ)发布2025年半年度报告，报告期内，公司实现营业收入28.17亿 元，同比下降0.71%。实现归属于上市公司股东的净利润4.22亿元，同比下降36.44%。实现归属于上市 公司股东的扣除非经常性损益的净利润4.26亿元，同比增长29.34%。基本每股收益0.2875元。 ...

公告称，净利润同比有所下降，主要由于2024年同期受大额一次性投资收益正向影响，对本报期利润同 比变化影响较大。 海普瑞（002399）(09989)公布2025年中期业绩，收入约27.91亿元，同比减少1.3%;母公司持有者的应占 溢利约4.22亿元，同比减少36.4%;每股盈利0.29元。 ...